Latest Breaking News On - Edison group us investor relations - Page 1 : comparemela.com

Biodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesDmitry zamoryakhinLaine yonkerInternational symposium on pediatric neuroColumbia university irving medical centerBiodexa pharmaceuticalsExchange commissionEdison group us investor relationsDiffuse midline gliomaOverall survivalInternational symposiumPediatric neuro oncologyPrivate securities litigation reform actUnited states securities

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update

Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesLaine yonkerDmitry zamoryakhinInternational symposium on pediatric neuroColumbia university irving medical centerExchange commissionBiodexa pharmaceuticalsEdison group us investor relationsDiffuse midline gliomaOverall survivalInternational symposiumPediatric neuro oncologyPrivate securities litigation reform actUnited states securities

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomLaine yonkerExchange commissionEdison group us investor relationsBiodexa pharmaceuticalsDuke cancer instituteCompany nasdaqBaptist md anderson cancer centerRecurrent glioblastomaGlioblastoma multiformeDiffuse midline gliomaPrivate securities litigation reform actUnited states securities

Biodexa Announces Allowance of U S Patent Covering Tolimidone

Biodexa Pharmaceuticals PLCBiodexa Announces Allowance of U.S. Patent Covering TolimidoneBiodexa plans to initiate a Phase 2 clinical program of t.

United kingdomUnited statesLaine yonkerBukwang pharmaceutical co ltdMelior pharmaceuticals incExchange commissionBiodexa pharmaceuticalsPfizer incTrademark officeCompany nasdaqEdison group us investor relationsAnnounces allowancePancreatic cellMelior pharmaceuticalsPrivate securities litigation reform actUnited states securities

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”)Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones.

United kingdomUnited statesProvention pharmaLaine yonkerMidatech pharmaExchange commissionBiodexa pharmaceuticalsActa neuropathologica communicationsEdison group us investor relationsInternational registryColumbia universityShareholder letter highlighting progressExpected milestonesStephen stampShareholder letterConvection enhanced delivery